SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile shares are facing significant volatility following an 'off-nominal' orbital insertion of its BlueBird 7 satellite by Blue Origin's New Glenn rocket. While the community is actively debating the potential for an orbital recovery versus a total loss, the long-term investment thesis remains anchored by the company's insurance coverage and its continued production roadmap for subsequent satellites.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing significant market momentum driven by its high-profile partnerships with NVIDIA and its growing leadership in neutral-atom quantum technology, leading to widespread community debate regarding valuation compared to quantum peers. Traders are actively monitoring technical breakouts and potential share unlock events, with many investors maintaining a high-conviction, long-term outlook on the stock's potential as a foundational quantum infrastructure play.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining significant community attention as investors position themselves for potential catalysts, including upcoming data at the AACR conference and ongoing anticipation regarding the Phase 3 REGAL trial's final events. While some community members are actively discussing a possible short squeeze and institutional positioning, others remain skeptical about clinical trial transparency and management strategy, keeping the stock in a highly debated, volatile position.

Sidus Space, Inc. is a space-as-a-service company. The firm focuses on commercial satellite design, manufacture, launch planning, mission operations and in-orbit support, and data collection with a vision to demonstrate space operations for new technologies, and deliver data and predictive analytics to both domestic and global customers. The company was founded by Carol M. Craig on July 17, 2012 and is headquartered in Merritt Island, FL.

Sidus Space Inc - Ordinary Shares - Class A

Sidus Space is trending due to a major expansion of its StarVault orbital data storage partnership with Lonestar, fueling heavy retail discussion about the company's long-term growth and potential for a parabolic breakout. Investors are actively debating the stock's high volatility, debating the impact of recent capital raises, and analyzing its position as a speculative play ahead of upcoming sector catalysts like the anticipated SpaceX IPO.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is surging following reports of a strategic partnership with Google to develop custom AI inference and memory processing chips, positioning the company as a key infrastructure player alongside Broadcom. While some investors remain cautious about the sustainability of the recent rally and potential index rebalancing volatility, the community is actively debating the stock's long-term growth trajectory in the data center and optical networking sectors.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing intense volatility and community-driven speculation following reports of a U.S. executive order aimed at fast-tracking ibogaine research for veterans. Traders are actively debating whether the move is a sustainable catalyst for a triple-digit squeeze on its low-float structure or a classic 'buy the rumor, sell the news' event ripe for a sharp reversal.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is currently in the spotlight as investors anticipate key clinical data releases, with sentiment fueled by broader policy shifts and administrative support for accelerating psychedelic research. Community members are actively debating the company's competitive positioning, clinical trial progress, and the potential for a favorable regulatory landscape for mental health treatments.

Schmid Group NV provides industrial equipment and services. It operates through following Technical equipment and processes; and Spare parts and services segments. The Technical equipment and processes segment includes mainly the sale of machines including installation and extended warranties. The Spare parts and services segment includes the sale of spare parts as well as services including repairs, modifications of machines and inspections. The company was founded in 1864 and is headquartered in Freudenstadt, Germany.

SCHMID Group N.V. - Ordinary Shares - Class A

SCHMID Group N.V.

SCHMID Group is generating significant volatility as the community debates the disconnect between its advanced glass substrate technology and a precarious financial situation plagued by dilution risk and liquidity concerns. While some investors are betting on the company's potential to play a critical role in AI and semiconductor hardware supply chains, skeptics remain focused on its history of earnings challenges and speculative market sentiment.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense market volatility and polarizing sentiment as investors clash over whether the token is a legitimate growth project or a coordinated pump-and-dump scheme. While proponents highlight upcoming project events and low circulating supply, critics are sounding the alarm over insider ownership concentrations and alleged market manipulation, leaving the community deeply divided between those betting on a recovery and those warning of a total crash.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster Inc. is capturing significant investor attention following a stellar earnings report that highlighted record revenue, GAAP profitability, and strong growth in its software-attached business. The community is actively discussing Ouster's transition from a pure hardware vendor into a comprehensive 'Physical AI' perception platform, particularly bolstered by the integration of the Stereolabs acquisition and a growing role in autonomous industrial and defense ecosystems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC...

ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofORIC Pharmaceuticals, Inc. (Oricor the Company) (NASDAQ:ORIC) for violations of the securities laws.The investigation focuses on whether the Company issued false...

Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 6.5% - Still a Buy?

Oric Pharmaceuticals (NASDAQ:ORIC) Trading Up 6.5% - Here's Why...

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are currently covering the company...

Oric Pharmaceuticals (NASDAQ:ORIC) Trading 11.6% Higher - Time to Buy?

Oric Pharmaceuticals (NASDAQ:ORIC) Trading Up 11.6% - Here's Why...

Investors Purchase Large Volume of Oric Pharmaceuticals Call Options (NASDAQ:ORIC)

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) was the target of unusually large options trading activity on Thursday. Stock traders purchased 2,266 call options on the stock. This is an...

HC Wainwright Reaffirms Buy Rating for Oric Pharmaceuticals (NASDAQ:ORIC)

HC Wainwright reissued a "buy" rating and issued a $25.00 target price on shares of Oric Pharmaceuticals in a research note on Thursday...

<ul class="summary-bullets"><li>Jones Research maintained a ‘Buy’ rating on the stock with a $25 price target, according to The Fly.</li><li>Wedbush Securities lowered its price target to $17 from $20 but maintained an ‘Outperform’ rating.</li><li>Cantor Fitzgerald said Rinzimetostat’s efficacy appears comparable to competitor Mevrometostat from Pfizer</li></ul>Shares of Oric Pharmaceuticals (ORIC) plunged 28% on Wednesday as investors reacted to tolerability concerns tied to a higher dose of its prostate cancer drug, even as analysts said the sharp sell-off appears exaggerated.<a href="https://stocktwits.com/symbol/ORIC">ORIC shares</a> recorded their biggest intraday slump in more than four years.<h2 class="st-heading-2">Oric Selects 400 MG Dose Of Rinzimetostat</h2>On Tuesday, Oric <a href="https://stocktwits.com/news-articles/markets/equity/oric-falls-after-hours-on-safety-concerns-around-prostate-cancer-candidate/cZ7HT8GRIVz">announced</a> it selected a lower 400 mg dose of its investigational drug Rinzimetostat. In the Phase 1 trial involving patients with metastatic castration-resistant prostate cancer, the 600 mg dose showed a higher rate of side effects, dose interruptions, and discontinuations when combined with darolutamide.By contrast, the 400 mg dose demonstrated a more manageable safety profile, with mostly mild side effects and only limited severe (Grade 3) events. The company now plans to move forward with the lower dose in a global Phase 3 trial in the first half of 2026.<h2 class="st-heading-2">Analysts Say Selloff is Exaggerated</h2>Despite the sharp selloff, analysts suggest the reaction may be overdone. Jones Research noted that the data appears broadly in line with Pfizer’s competing drug Mevrometostat, while potentially offering a better safety profile, according to The Fly.The firm said the selloff ‘appears exaggerated,” pointing out that Oric’s data is still early, with only about five months of follow-up compared to nine to 10 months for Pfizer’s results. Jones &nbsp;Research maintained a ‘Buy’ rating on the stock with a $25 price target.Other firms, including Cantor Fitzgerald and Wedbush, highlighted that efficacy remains comparable. “Efficacy appears comparable to competitor Mevrometostat from Pfizer, with Rinzi showing a potentially better safety profile,” Cantor said. It has an ‘Overweight’ rating on Oric shares.<h2 class="st-heading-2">Wedbush Says Results broadly In Line With Pfizer’s Drug</h2>Meanwhile, David Nierengarten of Wedbush Securities lowered his price target to $17 from $20 while maintaining an ‘Outperform’ rating. The analyst said Oric’s Phase 1 prostate cancer results are broadly in line with Pfizer’s, even though Oric tested its drug in a sicker patient group.He added that while greater efficacy differences are ideal, better tolerability is important, especially for older patients on long-term treatment, and could influence doctors’ choices if both drugs are similarly effective.Despite the sharp selloff, retail sentiment turned ‘extremely bullish’ from ‘neutral’ a day earlier.One user said the stock has "really good upside potential"<stembedurl>http://stocktwits.com/LF5/message/649195078</stembedurl>The stock has gained more than 10% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/oric-falls-after-hours-on-safety-concerns-around-prostate-cancer-candidate/cZ7HT8GRIVz">ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Oric Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says Selloff 'Appears Exaggerated’

Oric shares tanked after the firm selected a lower 400 mg dose of its investigational drug for prostate cancer after its 600 mg dose showed a higher rate of side effects.

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says ‘Selloff Appears Exaggerated’

Equity

What's Behind The Drop In Oric Pharmaceuticals Stock Today?

Shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) are tumbling Wednesday after the company announced an update from the Phase 1b trial of rinzimetostat in combination with darolutamide in patients...

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down Following Analyst Downgrade

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down Following Analyst Downgrade...

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

Current Price	$10.75
Prev Close	$10.23
Open	$10.42
Dividend Yield	0.00%
50-Day Moving Average	$11.33
Beta	1.42
Avg. Volume	1.62M
PE Ratio	-7.10

52-Week High	$14.93
52-Week Low	$4.52
Market Capitalization	$1.08B
EPS (Annual)	-$1.47
Price to Book	2.76
Revenue Per Employee	$0.00

ORIC
ORIC Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ORIC News

ORICORIC Pharmaceuticals Inc